Aside from RP101, no small molecules have been developed as HSP27 inhibitors for cancer therapy, although functional HSP27 inhibition may be a good strategy for combination therapy with HSP90 inhibitors, or chemotherapeutic agents. This evidence concerns the gene HSPB1 and cancer.